Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group
Journal of Clinical Medicine · 03.07.2026 · 15 (13) · 5224
DOI: 10.3390/jcm15135224 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 03.07.2026. Verfasst von Emine Bihter Eniseler und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Manisa Celal Bayar University, Manisa 45030, Turkey. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Despite improved survival with immune checkpoint inhibitors, the optimal treatment after anti-PD-1 progression in metastatic melanoma remains unclear. This study compared survival outcomes and treatment responses between chemotherapy (CT)- and immunotherapy (IO)-based therapies administered after nivolumab progression in patients with BRAF-negative metastatic melanoma.
Methods
This multicenter retrospective study included patients with BRAF-negative metastatic melanoma who developed disease progression during nivolumab treatment. Post-progression systemic therapies were categorized as CT- or IO-based treatments. Treatment responses were assessed according to RECIST version 1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier method, and prognostic factors were evaluated using Cox regression analyses.
Results
A total of 141 patients were included. Following nivolumab progression, 107 (75.9%) received CT and 34 (24.1%) received IO. Based on best response to nivolumab, the objective response rate (ORR; CR + PR) was 55.1% in the CT group and 44.1% in the IO group. After post-nivolumab treatment, ORRs were 29.9% and 32.4% in the CT and IO groups, respectively, whereas complete response rates were higher with IO (21.2% vs. 3.0%). Median PFS was 4.17 months in the CT group and 3.9 months in the IO group (p = 0.403). Median OS was 7.83 and 8.17 months, respectively (p = 0.416). Elevated LDH level was identified as an independent adverse prognostic factor.
Conclusions
In this multicenter real-world cohort, no statistically significant differences in survival were observed between patients receiving CT or IO after nivolumab progression. Given the retrospective, non-randomized study design, these findings should not be interpreted as evidence of comparative treatment efficacy. The higher CR rate observed with IO should be interpreted cautiously due to potential selection bias. Prospective studies are warranted to define the optimal treatment strategy after anti-PD-1 failure.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Manisa Celal Bayar University, Manisa 45030, Turkey.
- Department of Medical Oncology, Dicle University, Diyarbakir 21280, Turkey.
- Department of Medical Oncology, Kahramanmaraş Sütçü İmam University, Kahramanmaraş 46050, Turkey.
- Department of Medical Oncology, Sakarya University, Adapazari 54100, Turkey.
- Department of Medical Oncology, Alanya Alaaddin Keykubat Üniversitesi, Alanya 07425, Turkey.
- Department of Medical Oncology, Mersin Training and Research Hospital, Mersin 33000, Turkey.
ORCID-Profile: Emine Bihter Eniseler, Atike Pinar Erdogan, Fatma Keskin Uzundere, Hasibe Bilge Gür, İsmail Beypınar, Sila Oksuz, Tuğba Başoğlu, Bilgin Demir, Bedriye Açıkgöz Yıldız, Mehmet Sinan Akarca, İlkay Tuğba Ünek, Mahmut Kara, Havva Yeşil, Ferhat Ekinci
Zitieren
APA
Eniseler, E. B., Erdogan, A. P., Şahbazlar, M., Keskin Uzundere, F., Şakalar, T., Gür, H. B., Hacıbekiroğlu, İ., Balcık, O. Y., Beypınar, İ., Savsar, M. G., Pempe, G., Oksuz, S., Başoğlu, T., Demirkıran, Ö., Demir, B., Açıkgöz Yıldız, B., Demiray, A. G., Akarca, M. S., Ünek, İ. T., …, & Ekinci, F. (2026). Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group. Journal of Clinical Medicine, 15(13), 5224. https://doi.org/10.3390/jcm15135224
Vancouver
Eniseler EB, Erdogan AP, Şahbazlar M, Keskin Uzundere F, Şakalar T, Gür HB, et al. Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group. Journal of Clinical Medicine. 2026;15(13):5224. doi:10.3390/jcm15135224
BibTeX
@article{Eniseler2026,
author = {Eniseler, Emine Bihter and Erdogan, Atike Pinar and Şahbazlar, Mustafa and Keskin Uzundere, Fatma and Şakalar, Teoman and Gür, Hasibe Bilge and Hacıbekiroğlu, İlhan and Balcık, Onur Yazdan and Beypınar, İsmail and Savsar, Mehmet Gürdal and Pempe, Gözde and Oksuz, Sila and Başoğlu, Tuğba and Demirkıran, Özge and Demir, Bilgin and Açıkgöz Yıldız, Bedriye and Demiray, Atike Gökçen and Akarca, Mehmet Sinan and Ünek, İlkay Tuğba and Kara, Mahmut and Urun, Muslih and Gökay, Ahmet Cebeli and Yeşil, Havva and Ekinci, Ferhat},
title = {Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {13},
pages = {5224},
doi = {10.3390/jcm15135224}
}
EUVIMED